SEC Form 4 · accession 0001313516-17-000001
PLx Pharma Inc. · PLXP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Emerson Jorden
Officer — Acting Chief Financial Officer · 10% Owner
Period of report
Jun 14, 2017
Accepted (ET)
Jun 16, 2017 · 2:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001497504
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 14, 2017 | P | 32,727 | $6.875 | A | 151,913 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantF1 | $7.50 | Jun 14, 2017 | P | 32,727 | A | Dec 15, 2017 | Jun 14, 2027 | Common Stock | 32,727 | 32,727 | D |
Explanation of responses
- F1Issued pursuant to a private placement in connection with the purchase of common stock in a registered direct offering.